An important step in countering antibiotic resistance has been made by researchers from IOCB Prague, the Institute of Microbiology and the Institute of Biotechnology of the CAS.

IOCB Prague opened its new branch in Boston, USA on October 18, 2024. The move puts the institute in proximity to scientific institutions, such as Harvard University, MIT, and Boston Medical Center.

Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants.

Even heavily modified double helices of DNA are stable enough to be used for special applications.

Scientists from Dr. Lenka Maletinska's team have developed a new substance that may help to solve the health limitations of obesity and Alzheimer's disease.

A research group led by Dr. Edward Curtis has developed two new types of catalytic DNA molecules (deoxyribozymes) that can reveal the presence of target molecules through fluorescence or color.

Technology from the laboratories of IOCB Prague has been given an extraordinary opportunity to succeed in the rapidly developing segment of gene therapy.

Pavel Hobza from the IOCB Prague and his team discovered improper hydrogen bond twenty years ago. Current discovery has the potential to simplify the previously adopted definition of the hydrogen bond.

A piece of software which enables researchers worldwide to speed up their work and helps them make scientific discoveries is expanding from science into commerce.

Dr Petr Cígler and his collaborators are working on refining molecular systems for transporting ribonucleic acid (RNA) molecules into cells.